Andreadis P, et al. - The efficacy and safety of semaglutide, a recently approved glucagon-like peptide 1 receptor agonist (GLP-1 RA) for type 2 diabetes, were assessed via analyzing randomized controlled trials comparing semaglutide with placebo or other antidiabetic agents. Researchers recognized 6 placebo-controlled and 7 active-controlled studies with subcutaneous semaglutide and only 1 trial with oral semaglutide. Outcomes suggested that semaglutide is a potent once-weekly GLP-1 RA. It significantly reduces HbA1c, body weight and systolic blood pressure, but, in association with increased incidence of gastrointestinal adverse events.